LaborForce Media | Dr. Kerri O’Brien | May 5, 2026. This article examines recent developments regarding GLP-1 and alcohol use disorder.
A new randomized controlled trial published in The Lancet reports that once-weekly semaglutide injections reduced heavy drinking days among adults with alcohol use disorder and obesity when used alongside cognitive behavioral therapy.
The findings were reported by Medscape Medical News in an article titled “GLP-1 Semaglutide Promising for Alcohol Use Disorder,” written by Pauline Anderson and published May 4, 2026. The Medscape article cites the original Lancet study led by Mette Kruse Klausen, MD, of Copenhagen University Hospital in Denmark.
The study enrolled 108 adults with both alcohol use disorder and obesity. Participants had a body mass index of at least 30, an Alcohol Use Disorders Identification Test score above 15, and at least six heavy drinking days per month before entering the trial. Participants were randomly assigned to receive either once-weekly semaglutide, titrated up to 2.4 mg, or placebo for 26 weeks. All participants were also offered up to 10 sessions of cognitive behavioral therapy focused on motivation, craving, and relapse prevention.
According to the NIH summary of the study, participants receiving semaglutide had a 41.1% reduction in heavy drinking days, which was 13.7 percentage points greater than the placebo group. The researchers also reported that blood-alcohol biomarkers supported the self-reported drinking data.
The Medscape report noted that semaglutide was also associated with improvements in several secondary outcomes, including total alcohol consumption, number of drinks per drinking day, alcohol craving, and alcohol exposure biomarkers. Participants in the semaglutide group also experienced greater weight loss than those receiving placebo.
Alcohol use disorder remains an area with limited medication options. Medscape reported that only three medications — disulfiram, acamprosate, and naltrexone — are currently approved by the FDA for alcohol use disorder. The article notes that GLP-1 receptor agonists, including semaglutide, are approved for diabetes and obesity and are being studied for possible effects on reward pathways and appetite regulation.
The study authors cautioned that more research is needed before semaglutide can be considered broadly applicable for alcohol use disorder. The trial included only participants with obesity, had a 26-week alcohol-related follow-up period, and included a predominantly White study population. Larger studies in more diverse populations, including people without obesity, are needed to determine whether the findings apply more broadly.
The NIH release also reported that the study team wants to examine GLP-1 treatment over a longer duration and in a larger population to confirm the findings. The original study is cited by NIH as: Mette Kruse Klausen et al., “Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial,” The Lancet, 2026. DOI: 10.1016/S0140-6736(26)00305-3.
Reported side effects were most commonly gastrointestinal, including nausea, reduced appetite, vomiting, abdominal pain, reflux, and constipation. Medscape reported that these events were more common in the semaglutide group but were mainly mild to moderate and transient. Four serious adverse events occurred during the trial — one in the semaglutide group and three in the placebo group — and all had resolved by the five-week post-trial follow-up.
An accompanying editorial, with first author Christian S. Hendershot of the Department of Population and Public Health Sciences at the University of Southern California, described the findings as “timely and compelling,” according to Medscape. The editorial also noted a reported number needed to treat of 4.3, suggesting that further study of GLP-1 therapies for alcohol use disorder could have significant public health implications if confirmed in broader populations.
The study was funded by the Research Foundation, Mental Health Services, Capital Region of Denmark; the Novo Nordisk Foundation; Novavi Foundation; Hartmann Foundation; and the Augustinus Foundation. Disclosure information for the study and commentary authors is available in the original publications.
What this could mean for unions and union members
For unions, benefit funds, and labor health leaders, this research may be worth watching as part of a broader conversation about behavioral health, obesity care, diabetes prevention, and substance use support. Semaglutide is not currently presented in this study as a stand-alone solution or as a broadly approved alcohol use disorder treatment, but the findings may open the door for future benefit discussions if additional research confirms safety and effectiveness. Union members who are concerned about alcohol use, weight, diabetes risk, or medication options should speak directly with their physician or qualified healthcare provider. Union leaders and benefit trustees may also want to ask their health plan partners, pharmacy benefit managers, employee assistance programs, and behavioral health vendors whether they are tracking the research on GLP-1 medications and alcohol use disorder, and whether future coverage models could responsibly support members who may benefit from integrated medical and behavioral health care.
Tags: